Multistrain Probiotics Reduces UC Depression and Anxiety Scores

Inclusion Criteria: 1. Male or female patients aged ≥18 2. Patients with mild-to-moderately active UC (defined as a SCCAI score of ≥ 5 and \< 12 and a colonoscopy will be performed to confirm the classification) 3. Patients with psychological dysfunction at screening based on hospital anxiety and depression scale (HADS), defined as HAD-A or HAD-D score ≥ 8 4. Signed Informed Consent obtained Exclusion Criteria: 1. Severe ulcerative colitis (SCCAI score ≥ 12) or toxic dilatation of the colon 2. Prior bowel (either intestine or colon) resection surgery 3. Patients with any other disease or condition which might interfere with their participation in the trial, including significant hepatic, renal, endocrine, respiratory, neurologic, immune deficiency, cardiovascular, malignant diseases, bleeding disorders, autoimmune diseases and schizophrenia. 4. Take the following treatment: 1. Antibiotics within 4 weeks prior to screening 2. Oral steroids within the past 4 weeks before screening 3. Acetyl-salicylic acid ≤100 mg/day as anti-platelet therapy or NSAIDs within 4 weeks prior screening 4. Consecutive consumption of probiotics in 4 weeks prior to enrollment 5. Topical or oral steroids within the past 4 weeks before screening 5. Patients requiring hospitalization or imminent need for surgery 6. Significant hepatic function abnormalities, defined as the values of serum ALT or AST ≥twice of the upper limit of normal value 7. Women who are planning or actual pregnancy or lactating during study period 8. Alcohol addiction (\>40 g of alcohol/day，equivalent to \>1 L of beer/day, 0.5 L of wine/day) 9. Patients with a history of a psychiatric condition other than anxiety or depression, use of opioids, antidepressants or anxiolytics in regular doses, illicit drug consumption 10. Patients participating or having participated in another clinical study 30 days prior to screening 11. Patients with one or more of the diseases: bacillary dysentery, amebic dysentery, chronic schistosomiasis, intestinal tuberculosis and Crohn's disease 12. Patients who are unwilling to comply with the protocol